glp 1 pancreatic cancer GLP-1 Risk: What New Data Reveal Glucagon-like peptide 1 receptor agonists

As research continues, we may find that this gut-derived hormone holds the key to not only reversing metabolic disease but also enhancing longevity and vitality

Between 1969 and 1971, work by John Brown and Raymond Pederson, together with the peptide chemistry expertise of Erik Jorpes and Viktor Mutt [67], led to the identification of the gastric inhibitory polypeptide (GIP), a 42-amino acid polypeptide that was named based on its potency to suppress gastric motility and gastric acid secretion [[68], [69], [70]]

Lixisenatideonce-daily glucagon-like peptide-1 receptor agonist in the management of type 2 diabetes

In many low- and middle-income countries, the cost can exceed an average workers annual income

Obesity (Silver Spring, Md)

What You Need to Know About GLP-1 Drug Injury Lawsuits in 2026 Understanding GLP-1 drugs personal injury lawsuits in 2026